Indication intelligence, analysis and sector perception

Pluristem Therapeutics (PSTI) initiates a Registered Direct Offering (RDO)

May 5, 2020 11:40am

Priced at $9.45, selling 1.587 million shares to raise $15 million

PSTI is trading +$0.45 or +4.81% at $9.81

PSTI has entered into definitive agreements with two (2) institutional investors

The net proceeds from the offering are expected to be approximately $15,000,000.

Pluristem intends to use the net proceeds from the offering for working capital, including funding towards its P2 study of PLX cell therapy in the treatment of complications arising from COVID-19 and other clinical trial activities, investment in capital equipment and other general corporate purposes.

The offering is expected to close on or before May 7, 2020, subject to customary closing conditions.

The Bottom Line: Kudos, not bad at all, with $16 million in the till, and up to €50 million (US$54.2 million) being made available from the EIB through three tranches over a period of 36 months. The Financing will not exceed 50% of the total cost of the applicable project. Each tranche will be disbursed following the achievement of certain clinical, regulatory and scaleup milestones. The first tranche is €20 million, followed by a second tranche of €18 million, and a third tranche of €12 million.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

5 hours 7 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.